The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis
Rheumatology · 10.07.2026 · 64 (4) · 322-331
DOI: 10.5114/reum/224664 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology, online erschienen am 10.07.2026. Verfasst von Krzysztof Michalak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Medical Sciences, University of Opole, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Systemic sclerosis (SSc) remains a challenge due to high mortality and resistance to treatment. Chimeric antigen receptor T-cell (CAR-T) technology (anti-CD19) may offer an opportunity for an immune system reset and long-term disease remission, eliminating the need for lifelong medication. Material and Methods This narrative review is based on a literature search in the PubMed and Scopus databases from 2023 to 2026. The main search phrases were: “CAR-T in systemic sclerosis”, “CAR-T scleroderma”, and “CAR-T SSc.” Results CD19-targeted CAR-T therapy led to significant clinical improvement across analyzed cases. The median modified Rodnan skin score decreased by 8–13 points within 3–6 months. Disease activity, measured by the European Scleroderma Trials and Research Group Activity Index (EUSTAR-AI), showed a mean improvement ranging from 2.1 to 4.2 points. Pulmonary function remained stable or improved, with forced vital capacity increasing by up to 7% in responders. The safety profile was manageable, primarily consisting of grade 1 cytokine release syndrome in approximately 75–80% of patients.
Conclusions
CD19-targeted CAR-T therapy is a promising investigational option for patients with refractory SSc. Limitations include small study groups and a lack of randomized controlled trials, warranting further validation in ongoing clinical studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Institute of Medical Sciences, University of Opole, Poland.
ORCID-Profile: Krzysztof Michalak, Gabriela Chlebowska, Oliwia Sędziak, Dariusz Woszczyk
Zitieren
APA
Michalak, K., Chlebowska, G., Sędziak, O., & Woszczyk, D. (2026). The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis. Rheumatology, 64(4), 322-331. https://doi.org/10.5114/reum/224664
Vancouver
Michalak K, Chlebowska G, Sędziak O, Woszczyk D. The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis. Rheumatology. 2026;64(4):322-331. doi:10.5114/reum/224664
BibTeX
@article{Michalak2026,
author = {Michalak, Krzysztof and Chlebowska, Gabriela and Sędziak, Oliwia and Woszczyk, Dariusz},
title = {The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis},
journal = {Rheumatology},
year = {2026},
volume = {64},
number = {4},
pages = {322--331},
doi = {10.5114/reum/224664}
}
EUVIMED